Testing the strength hand's grip could be a life-saver, as new study has shown that it's the easier and affordable way to predict heart attack and stroke risk.
As per an international study of almost 140000 adults from 17 culturally and economically diverse countries, weak grip strength is linked with shorter survival and a greater risk of having a heart attack or stroke.
The study also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.
The current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years. Grip strength was assessed using a handgrip dynamometer.
The findings show that every 5kg decline in grip strength was associated with a 16 percent increased risk of death from any cause; a 17 percent greater risk of cardiovascular death; a 17 percent higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7 percent) or a stroke (9 percent).
These associations persisted even after taking into account differences in other factors that can affect mortality or heart disease such as age, education level, employment status, physical activity level, and tobacco and alcohol use.
A low grip strength was linked with higher death rates in people who develop cardiovascular (eg, heart attack or stroke) and non-cardiovascular diseases (eg, cancer), suggesting that muscle strength can predict the risk of death in people who develop a major illness.
Lead author Dr Darryl Leong at the McMaster University, Hamilton, Canada, said that further research was needed to establish whether efforts to improve muscle strength were likely to reduce an individual's risk of death and cardiovascular disease.
The study is published in The Lancet.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
